bioAffinity Technologies, Inc. (Nasdaq: BIAF) announced on September 9, 2026, that it has received written notice from The Nasdaq Stock Market LLC confirming that the company has regained compliance with Nasdaq’s listing requirements.
According to the filing, the company was previously notified on July 30, 2026, that its listed securities had closed at less than $1.00 per share over a 30-day period (from June 16, 2026, through July 29, 2026). This failure triggered a non-compliance status with the Minimum Bid Price Rule (Listing Rule 5550(a)(2)).
The company noted that it was ineligible for a standard 180-calendar day compliance period because it had effected a reverse stock split within the prior year. An appeal was submitted on August 6, 2026, and a hearing before the Nasdaq Hearings Panel was scheduled for September 8, 2026.
On September 8, 2026, Nasdaq confirmed that the company has regained compliance with both the Minimum Bid Price Rule and Listing Rule 5560(a) (the Rights/Warrants Rule). As a result, the previously scheduled hearing was cancelled, and the company’s common stock and warrants will continue to be listed and traded on the Nasdaq Capital Market under the symbols BIAF and BIAFW, respectively.
As of September 8, 2026, the company reported 1,166,625 outstanding shares of common stock. The aggregate market value of the common stock was approximately $10.4 million based on the closing price on that date.
The company’s primary product, CyPath Lung, is a noninvasive test designed for the early detection of lung cancer in high-risk patients. The test utilizes advanced flow cytometry and proprietary artificial intelligence to identify cell populations in patient sputum.
